Detection of renal dysfunction by point-of-care creatinine testing in patients undergoing peripheral MR angiography

American Journal of Roentgenology

Volumn 197, Issue 2, 2011, Pages 430-435

  Kalisz, Kevin R ^a   Davarpanah, Amir H ^a   Usman, Asad A ^a   Collins, Jeremy D ^a   Carroll, Timothy J ^a   Carr, James C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Gadolinium based contrast agents; Nephrogenic systemic fibrosis; Renal insufficiency; Screening

Indexed keywords

CREATININE; GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEPHROGENIC SYSTEMIC FIBROSIS; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION DOSE; RISK ASSESSMENT; RISK FACTOR;

AGED; ANALYSIS OF VARIANCE; COMORBIDITY; CONTRAST MEDIA; CREATININE; FEMALE; GADOLINIUM DTPA; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEGLUMINE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; POINT-OF-CARE SYSTEMS; PREVALENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79960734663     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.5761     Document Type: Article

References (20)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356:1000-1001
2. Kribben A, Witzke O, Hillen O, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 2009; 53:1621-1628
3. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15:785-790 (Pubitemid 38156308)
4. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25:204-209 (Pubitemid 36706461)
5. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23:383-393 (Pubitemid 32938907)
6. U.S. Food and Drug Administration Website. Information for healthcare professionals gadolinium-based contrast agents for magnetic resonance imaging scans (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance), 12/2006. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142905.htm Published June 2006. Updated December 2006. Accessed December 23, 2010
7. American College of Radiology Website. Updated ACR screening recommendations on gadolinium-based MR contrast agents, renal disease patients, and nephrogenic systemic fibrosis (NSF). www.acr.org/ secondarymainmenucategories/quality-safety/mrsafety/recommendations-gadolinium- based.aspx. Published July 2007. Accessed December 23, 2010
8. Thomsen HS. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007; 17:2692-2696
9. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Radiology 2009; 250:371-377
10. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Radiology 2009; 253:689-696
11. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol 1998; 4:65-69 (Pubitemid 28237617)
12. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-254 [Erratum in Ann Intern Med 2008; 149:519]
13. Levey AS, Eckardt KU, Tsukamoto T, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089-2100 (Pubitemid 41623371)
14. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317-1324 (Pubitemid 33015522)
15. Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishnan J. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2004; 44:185-197 (Pubitemid 38962546)
16. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16:180-188 (Pubitemid 43073171)
17. Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging 2009; 30:1357-1363
18. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66:230-234
19. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007; 18:2636-2643 (Pubitemid 47531189)
20. Sena BF, Stern JP, Pandharipande PV, et al. Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire. AJR 2010; 195:424-428